Business Context and Reporting Period
This Form 8-K Current Report was filed by AbbVie Inc. on April 13, 2022, covering the event date of April 8, 2022. The filing addresses a significant change in executive leadership under Item 5.02.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
The primary material change reported is the departure of a senior executive:
- Michael E. Severino, Vice Chairman and President of AbbVie, will depart the company effective May 31, 2022.
- He is leaving to join a bioplatform innovation company as CEO-Partner and as CEO of one of its companies.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, future outlook, management commentary on operations, specific risks, contingencies, or unusual items. The document is limited to the announcement of the executive departure.
Investor Verification Checklist
- Confirm the exact effective date of Michael E. Severino's departure (May 31, 2022).
- Verify the identity of the successor to the roles of Vice Chairman and President.
- Review subsequent filings for any changes to the company's strategic direction following this leadership transition.